Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

Conversion from tacrolimus twice a day formulation to once-daily tacrolimus in kidney transplant recipients

D. Kamińska, M. Kuriata-Kordek, M. Boratyńska, K. Falkiewicz, M. Klinger

Ann Transplant 2008; 13(1): 38-39 :: ID: 880200


Background: The aim of the study was to assess pharmacokinetics of twice a day versus once-daily tacrolimus in kidney transplant recipients.
Material/Methods: The study included 44 stable kidney transplant recipients who were transplanted between 2001 and 2008. Among them were 21women and 23 men aged from 17 to 68 y. (45±13). Immunosuppressive therapy consisted of tacrolimus and mycophenolate mofetil in 28 cases, mycophenolate sodium in 6 cases, azathioprine in 3 cases and prednisone in 43 cases. Kidney allograft function was stable before conversion and eGFR were 50±16 ml/min. Patients were converted from twice a day tacrolimus to the same milligram-for-milligram daily dose of once-daily tacrolimus taken in the morning. Blood samples were collected just before and after 14 days of conversion. Tacrolimus trough levels in whole blood were assessed by the Abbott IMx system.
Results: The mean tacrolimus dose was 4.4±1.7 mg/day. The mean trough level before conversion was 6.9±1.9 ng/ml. After 14 days of conversion the mean through level was lower: 5.6±1.9 ng/ml (the decrease of 19%). After conversion 11 (25%) patients presented stable trough levels. Changes in tacrolimus concentration were observed in 33 (75%) patients. In 28 patients (64%) a decrease of trough level and in 5 patients (11%) an increase was noticed. The dose adjustment after conversion due to potential subtherapeutic levels was required in total of 16 (36%) patients. All the recipients presented stable allograft function during the observation period (>2 months) after conversion. Conclusions: The results provide evidence to support a safety 1:1 conversion from twice a day versus once-daily formulation of tacrolimus. Trough levels must be monitored carefully at the early post-conversion period since a dose adjustment may be required.

Keywords: Pharmacokinetics, immunosuppressive therapy, azathioprine


In Press

06 May 2022 : Original article  

Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...

Ann Transplant In Press; DOI: 10.12659/AOT.936293  

27 Apr 2022 : Review article  

A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.935170  

Most Viewed Current Articles

31 Dec 1969 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

31 Dec 1969 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

31 Dec 1969 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

31 Dec 1969 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358